-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Downgrades Outlook Therapeutics to Neutral

Benzinga·08/29/2025 16:51:29
Listen to the news
Guggenheim analyst Eddie Hickman downgrades Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral.